<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JCDSA</journal-id><journal-title-group><journal-title>Journal of Cosmetics, Dermatological Sciences and Applications</journal-title></journal-title-group><issn pub-type="epub">2161-4105</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/jcdsa.2016.64022</article-id><article-id pub-id-type="publisher-id">JCDSA-70731</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Direct Transplant of Melanocytes from Normal Donor Area into Vitiligenous Recipient Area by Intralesional Injection of Melanocytes Using Spade Like Needle Technique
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Khalifa</surname><given-names>E. Sharquie</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Adil</surname><given-names>A. Noaimi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Zahraa</surname><given-names>N. Al-Khafaji</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Department of Dermatology &amp;amp; Venereology, Baghdad Teaching Hospital, Medical City, Baghdad, Iraq</addr-line></aff><aff id="aff1"><addr-line>Department of Dermatology &amp;amp; Venereology, College of Medicine, University of Baghdad, Baghdad, Iraq</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>ksharquie@ymail.com(KES)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>06</month><year>2016</year></pub-date><volume>06</volume><issue>04</issue><fpage>174</fpage><lpage>179</lpage><history><date date-type="received"><day>25</day>	<month>June</month>	<year>2016</year></date><date date-type="rev-recd"><day>accepted</day>	<month>18</month>	<year>September</year>	</date><date date-type="accepted"><day>21</day>	<month>September</month>	<year>2016</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Background
  : 
  Vitiligo is a common autoimmune inflammatory skin disease, where there are different surgical techniques for treatment of stable patches of vitiligo
  
  
  <b> .</b>
  Objective
  :
   To find non-costly, minimally invasive, simple technique by direct melanocytes transplant by spade needle technique in treatment of vitiligo
  
  
  <b>.</b>
  
  
   
  Patients and Methods
  :
   This interventional, therapeutic, comparative study was done in Department of Dermatology, Baghdad Teaching Hospital, Baghdad, Iraq from April 2014-March 2015. Twenty patients with localized, generalized and segmental vitiligo were included. Full history and examination for each patient was done with 4 (20%) males and 16 (80%) females and their ages ranged from 9 - 40 (23.15 &#177; 11.44) years. Forty one patches in 20 patients treated by spade grafting technique and the donor and recipient sites were demarcated and anesthesia done by xylocaine 2% with adrenalin 1:100,000. Transplantation was started by using disposable needle gauge 18 (the sharp end of needle was cut by a scissor to make it a spade like) with medical syringe 5 ml supplied with normal saline. The micro-pieces were taken from donor site and transplanted directly, easily and rapidly into dermis of recipient site and followed by pushing normal saline and the procedure was repeated to cover all recipient sites
  
  
  <b> </b>
  with 5 mm distance between injection points. The surface area of the lesions was calculated and the reduction rate was estimated every month till the end of the 4th month period of the treatment
  
  
  <b>.</b>
  
  
   
  Results
  :
   Including 41 patches in 20 patients with the surface area of the patches ranged from 1.5 - 90 cm<sup>2</sup> (13.78
   &#177; 17.57)
   cm<sup>2</sup>. The mean &#177;SD of surface area of lesions was decreased from 
  13.78 &#177; 17.57 
  cm<sup>2</sup> at baseline visit to 
  13.61 &#177; 17.48
   cm<sup>2</sup> at the second visit (after 2 weeks ) which was statistically significant (p value ≤ 
  0.001
  ). The mean surface area continued to be reduced till reaching 
  12.20 &#177; 15.68
   cm<sup>2</sup>
   
  at the third visit and 
  12.01 &#177; 15.55 
  cm<sup>2</sup> at the fourth visit. All were statistically significant when compared to baseline visit. There was reduction in surface area 1.1% at two weeks, 9.93%, and 12.5% at the 2nd, 4th months respectively. Conclusions: Intradermal injection of melanocytes in patients with vitiligo by spade like needle was very quick and simple non-costly technique, and gave 12.5% reduction which could be repeated at different times until satisfactory re-pigmentation of vitiligenous skin is achieved
  .
 
</p></abstract><kwd-group><kwd>Direct Transplant of Melanocytes</kwd><kwd> Intralesional Injection of Melanocytes</kwd><kwd> Spade Like Needle</kwd><kwd> Vitiligo</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Vitiligo is an autoimmune inflammatory disease that could be very progressive or run a slow course, or some time could be very stable localized area like segmental vitiligo. And in general, there are 2 types of patients with vitiligo in regarding to medical therapy either patients have rapid response to treatment so called rapid responder, while other group with very poor response to treatment so called poor responder [<xref ref-type="bibr" rid="scirp.70731-ref1">1</xref>] .</p><p>In patients with localized stable patches vitiligo and those with stable but poorly response to treatment like segmental vitiligo, there is the main indication for surgical therapy [<xref ref-type="bibr" rid="scirp.70731-ref2">2</xref>] .</p><p>These surgical treatment options for vitiligo offer the potential for rapid and more desirable amounts of repigmentation [<xref ref-type="bibr" rid="scirp.70731-ref3">3</xref>] . The different modalities of surgical techniques include: tattooing, organ-cultured fetal skin allografting, epidermal culture grafting, melanocyte culture grafting, autologous noncultured melanocyte-kerati- nocyte cell transplantation, epidermal grafting by the suction blister technique, thin Thiersch split skin grafting, or miniature punch grafting [<xref ref-type="bibr" rid="scirp.70731-ref4">4</xref>] . And more recently Sharquie et al. invented a new simple technique by direct transplant of melanocytes using micrografting pieces from normal donor area into vitiligenous recipient area with 68% repigmentation rate in the first 4 months. In this technique, partial splitting skin was harvested and divided into micro-pieces that transplanted directly into vitiligenous skin by using needling puncture [<xref ref-type="bibr" rid="scirp.70731-ref1">1</xref>] . While the aim of this work is to use very easily simple non-costly, minimally invasive technique by dermabrading normal donor area, and then to be injected inside the dermis of vitiligenous skin using spade like needle.</p></sec><sec id="s2"><title>2. Patient and Methods</title><p>Twenty patients with vitiligo were enrolled in this case interventional, therapeutic, comparative study, 4 males, 16 females and their ages ranged from 9 - 40 years with a mean of 24.45, SD &#177; 10.43 years. All clinical types of vitiligo including the generalized, localized and segmental were treated. The number of vitiligo patches varied between patients, so the total number of treated patches was 41 (<xref ref-type="table" rid="table1">Table 1</xref>).</p><p>Inclusion criteria</p><p>Segmental and localized areas of vitiligo were included. In patient with generalized vitiligo some localized areas were selected and treated either because were cosmetically unacceptable areas or as the patient requested. Activity of the disease was recorded for each patient to fix the duration of stability of the disease (<xref ref-type="table" rid="table1">Table 1</xref>).</p><p>Exclusion criteria</p><p>These are including systemic diseases like: diabetes mellitus, hematological diseases like bleeding tendencies, or drug that prevent clotting, and immune compromised patients. All patients stopped their vitiligo treatment at least two months before intervention.</p><p>From each patient, formal consent was taken before starting therapy after full explanation about the nature of the disease, course, and the procedure of treatment, follow up, prognosis and the need for pre and post treatment photographs. Also, the ethical approval was performed by the Scientific Committee of the Scientific Council of Dermatology and Venereology―Iraqi Board for Medical Specializations. All patients were photographed by</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The types of vitiligo, stability of the disease, and the site of donor areas</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >No. of pt.</th><th align="center" valign="middle" >Age</th><th align="center" valign="middle" >Sex</th><th align="center" valign="middle" >Type of Vitiligo</th><th align="center" valign="middle" >No. of patches</th><th align="center" valign="middle" >Stability of the disease in months</th><th align="center" valign="middle" >Donor Site</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >Male</td><td align="center" valign="middle" >Generalized</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >Thigh</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >Generalized</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >Thigh</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >Generalized</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >Thigh</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >Male</td><td align="center" valign="middle" >Segmental</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >Arm</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >Segmental</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >Chest</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >Generalized</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >Thigh</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >Generalized</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >Thigh</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >Male</td><td align="center" valign="middle" >Segmental</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >Thigh</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >Localized</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >Back</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >Generalized</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >Thigh</td></tr><tr><td align="center" valign="middle" >11</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >Generalized</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >Thigh</td></tr><tr><td align="center" valign="middle" >12</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >Generalized</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >Unstable</td><td align="center" valign="middle" >Thigh</td></tr><tr><td align="center" valign="middle" >13</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >Generalized</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >Thigh</td></tr><tr><td align="center" valign="middle" >14</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >Generalized</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >Leg</td></tr><tr><td align="center" valign="middle" >15</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >Generalized</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >Unstable</td><td align="center" valign="middle" >Thigh</td></tr><tr><td align="center" valign="middle" >16</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >Localized</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >Thigh</td></tr><tr><td align="center" valign="middle" >17</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >Generalized</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >Thigh</td></tr><tr><td align="center" valign="middle" >18</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >Segmental</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" >Back</td></tr><tr><td align="center" valign="middle" >19</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >Generalized</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >Unstable</td><td align="center" valign="middle" >Thigh</td></tr><tr><td align="center" valign="middle" >20</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >Generalized</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >Unstable</td><td align="center" valign="middle" >Thigh</td></tr></tbody></table></table-wrap><p>Samsung Galaxy S4 combines 13 megapixel camera.</p><p>Technique of transplant</p><p>When patient lying in semi supine position in good illuminated room. The photo was taken to vitiligenous recipient area and also for donor site. The donor and recipient sites were demarcated and anesthesia by xylocaine 2% with adrenalin 1:100,000 was given. The idea of putting adrenalin is to stop bleeding during grafting and to make grafting more easily. Dermabrasion of normal donor areas was performed from different hidden in the body by using of ordinary surgical scalpel.</p><p>Transplantation was started by using disposable gauge 18 needle; its sharp end was cut by a scissor to make it a spade like (<xref ref-type="fig" rid="fig1">Figure 1</xref>) with medical syringe 5 ml supplied with normal saline.</p><p>The micro-pieces were taken from donor site by spade needle and transplanted directly, easily and rapidly into the dermis of recipient sites by needle puncture and followed by pushing normal saline and the procedure was repeated to cover all recipient sites with 5 mm distance between puncture points.</p><p>Follow up and evaluation of response in recipient area</p><p>Patients were evaluated every 2 weeks for the 1st month and then monthly for 3 months. Then patients were advised to have natural sunlight exposure every day for at least 15 minutes. After the next 2 weeks assessment of the start of pigment was carried out at the grafting areas. At 2 months the surface area of the new pigmentation was measured and compared with the surface area of the recipient patch before grafting then the rate of pigmentation was calculated by using transparent with square paper, and also to record any side effects.</p><p>Follow up and evaluation of donor area</p><p>After 2 weeks dressing was removed and then follow up was carried out for 2 weeks for the first month and then monthly for the next 3 months to watch for any Koebner’s phenomenon and complications.</p></sec><sec id="s3"><title>3. Results</title><p>Results included 41 patches in 20 patients with the surface area of the patches ranged between 1.5 - 90 cm<sup>2</sup> with a mean &#177; SD of 13.78 &#177; 17.57 cm<sup>2</sup>.</p><p>Mean surface reduction</p><p>The mean &#177; SD of surface area of lesions was decreased from 13.78 &#177; 17.57 cm<sup>2</sup> at baseline visit to 13.61 &#177; 17.48 cm<sup>2</sup> at second visit (after two weeks ) which was statistically significant (p value ≤ 0.001). The mean surface area continued to be reduced till reaching 12.20 &#177; 15.68 at third visit and 12.01 &#177; 15.55 at fourth visit. All were statistically significant when compared to baseline visit (<xref ref-type="table" rid="table2">Table 2</xref>).</p><p>Percent Reduction</p><p>There was reduction in surface area 1.1% at two weeks, 9.93%, and 12.5% at the 2nd, 4th months respectively (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><p>Pattern of repigmentation</p><p>The pattern of repigmentation was halo pigmentation in all patients who response.</p><p>Side effects</p><p>Donor site Koebner’s phenomena was seen in 4 patients from 20 (20%), this was noticed at third visit (two months after grafting), atrophic linear scaring in 2 patients 10%, and post inflammatory hyperpigmentation in 4 patients (20%).These side effects were disappeared at fourth months of follow up. while in treated patches there was no side effect during period of follow up.</p></sec><sec id="s4"><title>4. Discussion</title><p>When medical therapy of vitiligo has failed, surgical treatment is indicated and the main target of surgery is stable localized and segmental vitiligo [<xref ref-type="bibr" rid="scirp.70731-ref5">5</xref>] . The aim of all these procedures is to implant melanocytes from the normal skin into vitiligenous areas [<xref ref-type="bibr" rid="scirp.70731-ref6">6</xref>] . There many surgical procedures but most these methods are time consuming, costly and need sophisticated lab and personnel. Sharquie et al. invented new simple techniques for direct melanocytes transplant. The first one so called direct transplant of melanocytes from normal donor area in to vitiligenous skin by dermabrasion technique which gave 36.78% repigmentation rate after 6 months of operation [<xref ref-type="bibr" rid="scirp.70731-ref7">7</xref>] . The second technique, direct melanocytes transplant by micrografting needling technique and this gave</p><fig-group id="fig1"><label><xref ref-type="fig" rid="fig1">Figure 1</xref></label><caption><title> Spade like needle.</title></caption><fig id ="fig1_1"><label></label><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/8-1050366x7.png"/></fig><fig id ="fig1_2"><label></label><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/8-1050366x8.png"/></fig></fig-group><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The mean differences patch size before and after needling using spade like needle</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Variable</th><th align="center" valign="middle" >Categories</th><th align="center" valign="middle" >Number of patches</th><th align="center" valign="middle" >Mean &#177; SD</th><th align="center" valign="middle" >Z</th><th align="center" valign="middle" >p value</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >Patch size (cm<sup>2</sup>)</td><td align="center" valign="middle" >Before needling</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >13.78 &#177; 17.57</td><td align="center" valign="middle"  rowspan="2"  >−2.226</td><td align="center" valign="middle"  rowspan="2"  >&lt;0.001<sup>**</sup></td></tr><tr><td align="center" valign="middle" >2 weeks after needling</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >13.61 &#177; 17.48</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Patch size (cm<sup>2</sup>)</td><td align="center" valign="middle" >Before needling</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >13.78 &#177; 17.57</td><td align="center" valign="middle"  rowspan="2"  >−4.034</td><td align="center" valign="middle"  rowspan="2"  >&lt;0.001<sup>**</sup></td></tr><tr><td align="center" valign="middle" >2 months after needling</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >12.20 &#177; 15.68</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Patch size (cm<sup>2</sup>)</td><td align="center" valign="middle" >Before needling</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >13.78 &#177; 17.57</td><td align="center" valign="middle"  rowspan="2"  >−4.03</td><td align="center" valign="middle"  rowspan="2"  >&lt;0.001<sup>**</sup></td></tr><tr><td align="center" valign="middle" >4 months after needling</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >12.01&#177;15.55</td></tr></tbody></table></table-wrap><p><sup>*</sup>p value ≤ 0.05 was significant; <sup>**</sup>p value ≤ 0.05 was significant; Wilcoxon Signed Ranks Test.</p><fig id="fig2"  position="float"><label><xref ref-type="fig" rid="fig2">Figure 2</xref></label><caption><title> Showing 35 years old female with generalized vitiligo treated by spade micro grafting technique. (a), (b) at the 1st visit and (c) at 4 months</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/8-1050366x9.png"/></fig><p>61.36% repigmentation rate at four months. These two techniques were quick and non-costly and gave a very high success rate within short time, when compared with cultured and non-cultured melanocytes transplant techniques [<xref ref-type="bibr" rid="scirp.70731-ref8">8</xref>] - [<xref ref-type="bibr" rid="scirp.70731-ref11">11</xref>] .</p><p>The aim of present work is to find much quicker, simple and the least costly than others techniques, by taking debradated normal donor skin using a spade like needle to be injected into dermis of the vitiligenous site.</p><p>The results of present work showed that the repigmentation rate was 12.5% at 4 months. And this rate of pigmentation is high within short time but much lower than previous Sharquie et al. techniques. Accordingly because this technique very easy simple, it could be repeated every month until will full repigmentation of vitiligenous skin was reached.</p></sec><sec id="s5"><title>5. Conclusion</title><p>Intralesional injection of melanocytes by spade like needle was very quick and simple technique, and gave 12.5% reduction rate which could be repeated every month until achieving satisfactory repigmentation of vitiligenous skin.</p></sec><sec id="s6"><title>Disclosure</title><p>This study was an independent study and not funded by any drug companies.</p></sec><sec id="s7"><title>Cite this paper</title><p>Khalifa E. Sharquie,Adil A. Noaimi,Zahraa N. Al-Khafaji, (2016) Direct Transplant of Melanocytes from Normal Donor Area into Vitiligenous Recipient Area by Intralesional Injection of Melanocytes Using Spade Like Needle Technique. Journal of Cosmetics, Dermatological Sciences and Applications,06,174-179. doi: 10.4236/jcdsa.2016.64022</p></sec></body><back><ref-list><title>References</title><ref id="scirp.70731-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Sharquie, K.E., Noaimi, A.A. and Al-Mudaris, H.A. (2013) Melanocytes Transplantation in Patients with Vitiligo Using Needling Micrografting Technique. Journal of Drugs in Dermatology, 12, e74-e78.</mixed-citation></ref><ref id="scirp.70731-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Halder, R.M. and Young, C.M. (2000) New and Emerging Therapies for Vitiligo. Dermatologic Clinics, 18, 79-89. 
http://dx.doi.org/10.1016/S0733-8635(05)70149-2</mixed-citation></ref><ref id="scirp.70731-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Mahmoud, B.H., Hexsel, C.L. and Hamzavi, I.H. (2008) An Update on New and Emerging Options for the Treatment of Vitiligo. Skin Therapy Letter, 13, 1-6.</mixed-citation></ref><ref id="scirp.70731-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Savant, S.S. (2005) Surgical Therapy of Vitiligo: Current Status. Indian Journal of Dermatology, Venereology, and Leprology, 71, 307. http://dx.doi.org/10.4103/0378-6323.16778</mixed-citation></ref><ref id="scirp.70731-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Falabella, R. and Barona, M.I. (2009) Update on Skin Repigmentation Therapies in Vitiligo. Pigment Cell &amp; Melanoma Research, 22, 42-65. http://dx.doi.org/10.1111/j.1755-148X.2008.00528.x</mixed-citation></ref><ref id="scirp.70731-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Rusfianti, M. and Wirohadidjodjo, Y.W. (2006) Dermatosurgical Techniques for Repigmentation of Vitiligo. International Journal of Dermatology, 45, 411-417. http://dx.doi.org/10.1111/j.1365-4632.2006.02486.x</mixed-citation></ref><ref id="scirp.70731-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Sharquie, K.E., Noaimi, A.A. and Al-Mudaris, H.A. (2013) Direct Melanocytes Transplant from Normal Donor Area into Vitiliginous Recipient Area by Dermabrasion Technique. Journal of Drugs in Dermatology, 12, 74-78.</mixed-citation></ref><ref id="scirp.70731-ref8"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mulekar</surname><given-names> S.V. </given-names></name>,<etal>et al</etal>. (<year>2003</year>)<article-title>Melanocyte-Keratinocyte Cell Transplantation for Stable Vitiligo</article-title><source> International Journal of Dermatology</source><volume> 42</volume>,<fpage> 132</fpage>-<lpage>136</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.70731-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Olsson, M.J. and Juhlin, L. (1998) Leucoderma Treated by Transplantation of a Basal Cell Layer Enriched Suspension. British Journal of Dermatology, 138, 644-648.</mixed-citation></ref><ref id="scirp.70731-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Czajkowski, R., Placek, W., Drewa, T., Kowaliszyn, B., Sir, J. and Weiss, W. (2007) Autologous Cultured Melanocytes in Vitiligo Treatment. Dermatologic Surgery, 33, 1027-1036.</mixed-citation></ref><ref id="scirp.70731-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Lotti, T., Gori, A., Zanieri, F., Colucci, R. and Moretti, S. (2008) Vitiligo: New and Emerging Treatments. Dermatologic Therapy, 21, 110-117. http://dx.doi.org/10.1111/j.1529-8019.2008.00178.x</mixed-citation></ref></ref-list></back></article>